US-based Greenlight Guru, a medical device quality management software provider, has integrated its platform with issue and project tracking tool Jira.
Medical device companies can use the integrated system to manage product development and post-market quality for their software-based devices.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Greenlight added that the combined platform will allow companies to minimise non-compliance risk by ensuring the capture of relevant Jira artefacts in their quality management system.
Greenlight Guru Quality Assurance and Regulatory Affairs co-founder and vice-president Jon Speer said: “Modern medical devices contain hardware, software and firmware levels, each of which is commonly owned and developed by cross-functional teams.
“This integration allows product managers to track and maintain compliance mandated by regulatory bodies while enabling software development in one of the most popular and adaptable management environments in the industry.”
Software development teams can also use Jira’s agile functionality to track implementation work and issues associated with software components.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt also facilitates simultaneous traceability to their design control and risk management system of record within Greenlight.
Greenlight Guru co-founder and CEO David DeRam added: “The agile development approach has helped bring about world-class technology like Gmail, Spotify and Salesforce.
“Greenlight Guru and Jira are the industry leaders in their respective fields; and, this new partnership will help usher in the next generation of quality-focused medical devices to market.”
The firm’s quality management software platform has been specifically designed for medical device companies. It is said to aid companies in obtaining safer products and simplify regulatory compliance.
